Myth-buster
A 48-week trial found high-dose vitamin B3 slowed decline on one clinical scale in early Alzheimer disease — but failed to budge the key brain biomarkers it was designed to change.
This single small trial hints at a possible clinical benefit, but the lack of effect on biomarkers and the fact that the positive result was a secondary analysis mean the picture is far from settled — treat with caution.
In a 48-week trial of 47 people with early Alzheimer disease, taking 3,000 mg daily of nicotinamide (a form of vitamin B3) did not significantly change levels of tau or amyloid proteins in spinal fluid — the main targets researchers were looking at. However, on a clinician-rated scale of dementia severity (CDR-SB), the treated group showed about 1.4 points less worsening than placebo, a difference that was statistically significant before adjusting for multiple comparisons. Because this was a small, early-phase study with a mixed bag of results, the finding is intriguing but not enough to recommend high-dose B3 for Alzheimer.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin B3 for Improved Clinical Dementia Rating — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 47
- 2025-01-14
- Neurology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.